A new PBS listing for Bronchitol,
developed by Australian
pharmaceutical firm Pharmaxis,
has taken effect from today, which
simplifies access to the medication
for cystic fibrosis patients.
Bronchitol (mannitol) is a dry
powder delivered via a portable
inhaler which can improve lung
function for CF sufferers.
The new listing removes a
requirement for patients to show
a 10% increase in lung function
in order to continue having their
treatment subsidised.
The “10% increase rule” will be
replaced with a new set of criteria
which will give greater flexibility to
patients and their clinical team in
deciding on continuing treatment.
A lung function test will still be
involved but this will occur after
three months rather than four
weeks of treatment.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Nov 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Nov 13
PEAK industry bodies have welcomed Labor Government’s 2024-25 Commonwealth Budget handed down last night, which introduced financial relief measures aimed at assisting patients and community pharmacies.
AFFORDABLE healthcare for more Australians was highlighted in yesterday’s Federal Budget, with funds allocated to services for Aboriginal and Torres Strait Islander people.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.